<DOC>
	<DOCNO>NCT02852239</DOCNO>
	<brief_summary>To characterize pharmacokinetics safety dabrafenib follow single 100 mg oral dose subject severe renal impairment end stage renal disease dialysis .</brief_summary>
	<brief_title>Pharmacokinetics Dabrafenib Subjects With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Other renal impairment , subject good health determine clinically significant finding medical history , physical exam , laboratory evaluation Subjects must BMI 18.0 kg/m2 36 kg/m2 , body weight least 50 kg 120 kg Additional criterion renal impairment subject : Subjects must stable renal disease without evidence renal progression past 28 day prior dose Additional criterion healthy matched subject : Matched least 1 renal impairment subject race , age ( +/10 year ) , gender weight ( +/10 % ) An absolute GFR least 90 ml/min Significant acute illness within two week prior dose History presence clinically significant ECG abnormality family history presence prolong QTinterval syndrome History current diagnosis cardiac disease indicate significant risk safety subject participate study uncontrolled significant cardiac disease Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug . History malignancy organ system , treat untreated , within 5 year , regardless recurrence metastasis . History drug alcohol abuse within 6 month prior dose evidence abuse indicate laboratory value screen baseline . Additional exclusion renal impairment subject : Severe albuminuria &gt; 300 mg/day . Subjects undergo method dialysis . Subjects renal impairment due hepatic disease ( hepatorenal syndrome ) . Subjects clinically significant abnormal finding , consistent clinical disease , upon physical examination , ECG laboratory evaluation . Other protocoldefined inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Renal impairment</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Clinical pharmacology study</keyword>
	<keyword>DRB436</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>normal renal function</keyword>
	<keyword>impaired renal function</keyword>
</DOC>